Search Results - "Lackner, M R"

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter by Qu, X, Sandmann, T, Frierson, H, Fu, L, Fuentes, E, Walter, K, Okrah, K, Rumpel, C, Moskaluk, C, Lu, S, Wang, Y, Bourgon, R, Penuel, E, Pirzkall, A, Amler, L, Lackner, M R, Tabernero, J, Hampton, G M, Kabbarah, O

“…Key molecular drivers that underlie transformation of colonic epithelium into colorectal adenocarcinoma (CRC) are well described. However, the mechanisms…”
Get full text

The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy by Cummings, CA, Peters, E, Lacroix, L, Andre, F, Lackner, MR

“…The workhorse instruments of this era were capillary electrophoresis instruments that employed fluorescent dye terminators to read out the sequence of up to 96…”
Get full text

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer by Arthur, L. M., Turnbull, A. K., Renshaw, L., Keys, J., Thomas, J. S., Wilson, T. R., Lackner, M. R., Sims, A. H., Dixon, J. M.

“…The phosphatidylinositol-3-kinase pathway plays an important role in proliferation, migration and survival in breast cancer and may play a role in resistance…”
Get full text

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer by Liu, J.F., Moore, K.N., Birrer, M.J., Berlin, S., Matulonis, U.A., Infante, J.R., Wolpin, B., Poon, K.A., Firestein, R., Xu, J., Kahn, R., Wang, Y., Wood, K., Darbonne, W.C., Lackner, M.R., Kelley, S.K., Lu, X., Choi, Y.J., Maslyar, D., Humke, E.W., Burris, H.A.

“…MUC16 is a tumor-specific antigen overexpressed in ovarian (OC) and pancreatic (PC) cancers. The antibody–drug conjugate (ADC), DMUC5754A, contains the…”
Get full text

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers by Fumagalli, D., Wilson, T.R., Salgado, R., Lu, X., Yu, J., O'Brien, C., Walter, K., Huw, L.Y., Criscitiello, C., Laios, I., Jose, V., Brown, D.N., Rothé, F., Maetens, M., Zardavas, D., Savas, P., Larsimont, D., Piccart-Gebhart, M.J., Michiels, S., Lackner, M.R., Sotiriou, C., Loi, S.

“…Estrogen receptor-positive (ER+) breast cancers (BCs) constitute the most frequent BC subtype. The molecular landscape of ER+ relapsed disease is not well…”
Get full text

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer by Huw, L-Y, O'Brien, C, Pandita, A, Mohan, S, Spoerke, J M, Lu, S, Wang, Y, Hampton, G M, Wilson, T R, Lackner, M R

“…Agents targeting the PI3K/mTOR signaling axis have shown promise in early-phase clinical trials and are currently being studied in later stages of clinical…”
Get full text

Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology by Okrah, K., Tarighat, S., Liu, B., Koeppen, H., Wagle, M. C., Cheng, G., Sun, C., Dey, A., Chang, M. T., Sumiyoshi, T., Mounir, Z., Cummings, C., Hampton, G., Amler, L., Fridlyand, J., Hegde, P. S., Turley, S. J., Lackner, M. R., Huang, S. M.

“…Hepatocellular carcinoma (HCC) develops in the context of chronic inflammatory liver disease and has an extremely poor prognosis. An immunosuppressive tumor…”
Get full text

Genetic Analysis of the Caenorhabditis elegans MAP Kinase Gene mpk-1 by Lackner, Mark R, Kim, Stuart K

“…The Caenorhabditis elegans mpk-1 gene encodes a MAP kinase protein that plays an important role in Ras-mediated induction of vulval cell fates. We show that…”
Get full text

A MAP kinase homolog, mpk-1, is involved in ras-mediated induction of vulval cell fates in Caenorhabditis elegans by Lackner, M R, Kornfeld, K, Miller, L M, Horvitz, H R, Kim, S K

“…During development of the Caenorhabditis elegans hermaphrodite, the gonadal anchor cell induces nearby Pn.p cells to adopt vulval fates. The response to this…”
Get full text

MAP Kinase Signaling Specificity Mediated by the LIN-1 Ets/LIN-31 WH Transcription Factor Complex during C. elegans Vulval Induction by Tan, Patrick B, Lackner, Mark R, Kim, Stuart K

“…The let-23 receptor/ mpk-1 MAP kinase signaling pathway induces the vulva in C. elegans. We show that MPK-1 directly regulates both the LIN-31 winged-helix and…”
Get full text

Abstract P2-08-02: Interaction of PIK3CA mutation subclasses with response to preoperative treatment with the PI3K inhibitor pictilisib in patients with estrogen receptor-positive breast cancer by Schmid, P, Pinder, S, Wheatley, D, Zummit, C, Macaskill, EJ, Hu, J, Price, R, Bundred, N, Hadad, S, Shia, A, Sarker, S-J, Lim, L, Mousa, K, O'Brien, C, Wilson, TR, Lackner, MR, Gendreau, S, Gazinska, P, Korbie, D, Trau, M, Mainwaring, P, Thompson, A, Purushotham, A

“…Abstract Background: Although preclinical data suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance, results from randomized…”
Get full text

Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD) by Spoerke, JM, Daemen, A, Chang, C-W, Giltnane, J, Metcalfe, C, Dickler, MN, Bardia, A, Perez Fidalgo, JA, Mayer, IA, Boni, V, Winer, EP, Hamilton, EP, Bellet, M, Urruticoechea, A, Gonzalez Martin, A, Cortes, J, Martin, M, Gates, M, Cheeti, S, Fredrickson, J, Wang, X, Friedman, LS, Liu, L, Li, R, Chan, IT, Mueller, L, Milan, S, Lauchle, J, Humke, EW, Lackner, MR

“…Abstract Background: Modulation of estrogen activity and/or synthesis is the mainstay therapeutic strategy in the treatment of ER positive breast cancer…”
Get full text

Abstract P6-07-08: The complete spectrum of ESR1 mutations from 7590 breast cancer tumor samples by Spoerke, JM, Schleifman, E, Clark, TA, Young, G, Nahas, M, Kennedy, M, Young, L, Chmielecki, J, Otto, GA, Lipson, D, Wilson, TR, Gendreau, S, Lackner, MR

“…Abstract Background: Approximately 70% of newly diagnosed breast cancers express estrogen receptor alpha (ERα), and are treated with agents that block ER…”
Get full text

Abstract PD1-1: PI3-kinase mutations in recurrences in patients with estrogen receptor positive breast cancer by Dixon, JM, Renshaw, L, Keys, J, Sims, A, Thomas, J, Wilson, TR, Lackner, MR

“…Abstract INTRODUCTION Activation of the Phosphatidylinositide 3-kinase/mammalian target of rapamycin (PI3K)/mTOR pathway is thought to play a role in the…”
Get full text

Abstract P6-05-09: Development of a predictive biomarker gene expression signature for the PIK3CA inhibitor, GDC-0032, in breast cancer cells by Savage, H, O'Brien, C, Spoerke, J, Huw, L, Wallin, J, Friedman, L, Lackner, MR, Wilson, TR

“…Abstract Introduction The PI3-Kinase pathway is one of the most commonly mutated pathways in cancer and plays a major role in cell proliferation and survival…”
Get full text

Abstract P5-13-01: Transcript analysis of PI3K and immune-related genes and gene signatures in the pre- and post-treatment samples from the window of opportunity study of anastrozole and anastrozole with pictilisib (GDC-0941) in patients with HR-positive early breast cancer (OPPORTUNE study) by Schmid, P, Pinder, SE, Bundred, N, Wheatley, D, Macaskill, J, Zammit, C, Hu, J, Price, R, Shia, A, Lim, L, Parker, P, Molinero, L, Yu, J, O'Brien, C, Wilson, T, Savage, H, Derynck, M, Lackner, MR, Amler, L, Purushotham, A, Thompson, A, Gendreau, S

“…Abstract Background: The OPPORTUNE Study randomized postmenopausal patients (pts) to receive 2-week preoperative treatment with anastrozole (ANA) plus…”
Get full text

Abstract P6-05-12: Comprehensive molecular analysis of estrogen receptor positive breast cancer to determine clinically actionable alterations by O'Brien, C, Savage, H, Huw, L, Fumagalli, D, Salgado, R, Criscitello, C, Pugliano, L, Laios, I, Piccart, M, Michiels, S, Sotiriou, C, Loi, S, Lackner, MR, Wilson, TR

“…Abstract Introduction. Understanding the genetic landscape of estrogen receptor positive breast caner is critical for defining clinically actionable alleles…”
Get full text

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors by Lackner, Mark R., Kindt, Rachel M., Carroll, Pamela M., Brown, Katherine, Cancilla, Michael R., Chen, Changyou, de Silva, Heshani, Franke, Yvonne, Guan, Bo, Heuer, Tim, Hung, Tak, Keegan, Kevin, Lee, Jae Moon, Manne, Veeraswamy, O’Brien, Carol, Parry, Dianne, Perez-Villar, Juan J., Reddy, Rajashekar K., Xiao, Hong, Zhan, Hangjun, Cockett, Mark, Plowman, Greg, Fitzgerald, Kevin, Costa, Michael, Ross-Macdonald, Petra

“…A chemical genetics approach identified a cellular target of several proapoptotic farnesyl transferase inhibitors (FTIs). Treatment with these FTIs caused…”
Get full text

Facilitation of synaptic transmission by EGL-30 Gqalpha and EGL-8 PLCbeta: DAG binding to UNC-13 is required to stimulate acetylcholine release by Lackner, M R, Nurrish, S J, Kaplan, J M

“…We show that neurotransmitter release at Caenorhabditis elegans neuromuscular junctions is facilitated by a presynaptic pathway composed of a Gqalpha (EGL-30),…”
Get full text

Facilitation of Synaptic Transmission by EGL-30 G sub(q) alpha and EGL-8 PLC beta : DAG Binding to UNC-13 Is Required to Stimulate Acetylcholine Release by Lackner, M R, Nurrish, S J, Kaplan, J M

“…We show that neurotransmitter release at Caenorhabditis elegans neuromuscular junctions is facilitated by a presynaptic pathway composed of a G sub(q) alpha…”
Get full text